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Abstract
People with mood disorders often have disruptions in their circadian rhythms. Recent molecular genetics has linked
circadian clock genes to mood disorders. Our objective was to study two core circadian clock genes, CRY1 and CRY2 as well
as TTC1 that interacts with CRY2, in relation to depressive and anxiety disorders. Of these three genes, 48 single-nucleotide
polymorphisms (SNPs) whose selection was based on the linkage disequilibrium and potential functionality were genotyped
in 5910 individuals from a nationwide population-based sample. The diagnoses of major depressive disorder, dysthymia and
anxiety disorders were assessed with a structured interview (M-CIDI). In addition, the participants filled in self-report
questionnaires on depressive and anxiety symptoms. Logistic and linear regression models were used to analyze the
associations of the SNPs with the phenotypes. Four CRY2 genetic variants (rs10838524, rs7121611, rs7945565, rs1401419)
associated significantly with dysthymia (false discovery rate q,0.05). This finding together with earlier CRY2 associations
with winter depression and with bipolar type 1 disorder supports the view that CRY2 gene has a role in mood disorders.
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Introduction
Circadian rhythms are about 24-hour oscillations in physio-
logical processes that allow humans to anticipate routine
changes in the environment. The rhythms are generated by
the internal clock, the principal one being located in the
suprachiasmatic nucleus of the anterior hypothalamus in the
brain. At the molecular level, the transcription of a network of
genes is switched on and off following the approximate 24-hour
pattern. A feedback loop is initiated by binding of CLOCK
protein [1] with aryl hydrocarbon receptor nuclear translocator-
like (ARNTL) protein [2]. The heterodimer then activates the
transcription of a large set of genes and among them the period
(PER1, PER2, PER3) and cryptochrome (CRY1, CRY2) genes.
Again, the encoded proteins form heterodimers (PER-with-CRY
dimers) which translocate back to the nucleus and inhibit the
CLOCK-with-ARNTL mediated transcription, thereby repress-
ing their own transcription [3]. In addition, nuclear receptors
together with their co-activators and co-repressors feed back to
ARNTL [4].
The cryptochrome genes may be of key importance here,
because of their unique role in the core of these feedback loops
[3,5,6]. The nuclear ratio of CRY1 to CRY2 proteins controls the
period of the circadian clock [5] and the effects of CRY2 on
circadian regulation are sensitive to the dosage of CRY1 [7].
Findings from knock-out mice suggest that without CRY2 the
circadian period is lengthened similar to ‘‘evening owls’’, whereas
without CRY1 it is shortened [8,9]. Furthermore, CRY2 appears to
play a critical role in tuning the suprachiasmatic nucleus to 24
hour cycle by opposing and titrating the decelerating action of
CRY1 [7].
‘‘Evening owls’’ are known to have increased risk for anxiety
and depressive symptoms [10,11] that may develop into depressive
disorders [12,13]. Furthermore, dysfunction of signaling pathways
involving CRY1 and CRY2 might lead into depressive behaviors
as follows. Interaction of CRY1 and CRY2 proteins directly with
the Gsa subunit of heterotrimeric G protein [14] and with
adenylyl cyclase [15] reduces the accumulation of cyclic adenosine
monophosphate in response to G protein-coupled receptor
activation and inhibits downstream reactions [15,16]. If this
inhibition is not appropriate, the inhibitory tone on cyclic
adenosine monophosphate signaling is overruled, leading to the
activation of cascades downstream, such as cyclic adenosine
monophosphate response element-binding protein activity, and to
the increase in depressive-like behaviors [17].
Disrupted or misaligned circadian rhythms and circadian gene
expression are often found in major depressive disorder and
bipolar disorder, with or without a seasonal pattern [18,19]. Since
the original finding [20], there is a growing evidence that genetic
variations in the core circadian clock genes associate with mood
and anxiety disorders [21]. In addition, these genetic variations
associate with sleep and metabolic disorders [22] that are often
comorbid conditions with mood and anxiety disorders. With the
focus on the cryptochrome genes, earlier studies have indicated
CRY1 genetic variants in major depressive disorder [23] and CRY2
genetic variants in seasonal affective disorder, winter depression in
particular, and in bipolar type 1 disorder [24,25].
The aim of the current paper is to study the associations of
CRY1, CRY2 and TTC1 genes in depressive and anxiety disorders.
In addition to the two cryptochrome genes, TTC1 was selected in
order to analyze epistasis, if any, between the TTC1 and CRY2
genes, because the TTC1 protein interacts physically with CRY2
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[26]. The present work extends the earlier studies by deeper
linkage disequilibrium (LD) coverage of the genes, by including
potential functional variants, by using a large sample derived
randomly from the general population, by assessment based on
both a diagnostic interview and self-reports, and by analysis of
diverse phenotype information. Here we report a significant
association of CRY2 genetic variants with dysthymia.
Materials and Methods
Ethics Statement
The ethics committees of the National Public Health Institute
and the Helsinki and Uusimaa Hospital District accepted the study
protocol and its ethical approval, and all participants provided a
written informed consent.
Subjects
This study was part of a nationwide health interview and
examination survey, Health 2000. The survey included a health
status examination and the Munich-Composite International
Diagnostic Interview (M-CIDI) [27]. M-CIDI is a valid and
reliable instrument for the assessment of depressive, anxiety and
alcohol use disorders, yielding diagnoses according to Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV). In addition, participants gave venous blood samples for
DNA extraction and filled in two sets of questionnaires. The
sample for our current study from the Health 2000 participants
aged 30 years and older (n = 8028) included 5910 individuals
(3283 women, 2627 men) who had given blood samples, taken part
to the M-CIDI interview and filled in the self-report on seasonal
changes in mood and behavior. The study design and methods
have been described in detail elsewhere (http://www.terveys2000.
fi/indexe.html).
Phenotypes
Altogether 12 phenotypes related to mental well-being (diagno-
ses according to DSM-IV and psychometric scales) were analyzed
(Table 1). Mental disorders analyzed in the current study included
major depressive disorder, dysthymia, depressive disorders (major
depressive disorder, dysthymia), panic disorder, anxiety disorders
(panic disorder w/o agoraphobia, generalized anxiety disorder,
social phobia, agoraphobia), and the comorbid conditions of
depressive, anxiety and alcohol use disorders (alcohol dependence
and abuse), as assessed with the M-CIDI. The controls did not
have any diagnosis of mental disorders nor met any sub-threshold
criteria as assessed with the M-CIDI.
In addition to attending the diagnostic interview, the partic-
ipants completed the following four self-reports that were also
analyzed: 1) a modified 21-item Beck Depression Inventory (BDI;
[28]), as adapted and validated for the Finnish population [29], 2)
the 16-item Maslach Burnout Inventory (MBI; [30]); 3) the 12-
item General Health Questionnaire (GHQ; [31]), and 4) a
modified [32] 7-item Seasonal Pattern Assessment Questionnaire
(SPAQ; [33]). These questionnaires give quantitative information
about depressive and anxiety symptoms.
Gene and SNP Selection
Three genes of interest were selected: CRY1, CRY2 and TTC1.
The SNP selection was based on phase 3 data of the HapMap
database (http://www.hapmap.org/) and done using the Tagger
program included in the Haploview 4.1 software [34]. Information
about the LD within the chosen areas of the genome was used to
select an optimal set of SNPs capturing most of the genetic
variation. Areas of the genome covered were the genes and 10 kb
of their 59 and 39 flanking regions. For CRY1, this area of interest
was 122 kb (chr12:105,899–106,021 kb, NCBI36/hg18 assembly)
in size, whereas for CRY2 it was 56 kb (chr11:45,815–45,871 kb)
and for TTC1 77 kb (chr5:159,358–159,435 kb).
The HapMap database included 21, 34 and 15 SNPs having a
minor allele frequency (MAF) .5% in the European population
(CEU and TSI) for the areas containing the CRY1, CRY2 and
TTC1 genes, respectively. The aim was to capture all these SNPs
by setting the limit for the pair-wise r2 to $0.9. Based on this
criterion, ten CRY1 SNPs, ten CRY2 SNPs and nine TTC1 SNPs
Table 1. Number of subjects in mental health related phenotypes (DSM-IV based diagnoses and quantitative scores on
psychometric scales) analyzed in the study.
All Women Men
Phenotypes analyzed Cases Controls Cases Controls Cases Controls
Depressive disorders 354 3871 242 2135 112 1736
Major depressive disorder 267 3871 183 2135 84 1736
Dysthymia 136 3871 90 2135 46 1736
Anxiety disorders 221 3871 137 2135 84 1736
Panic disorder 106 3871 71 2135 35 1736
Comorbid depressive disorders 145 3871 84 2135 61 1736
Comorbid anxiety disorders 117 3871 63 2135 54 1736
Comorbid alcohol use disorders 105 3871 38 2135 67 1736
BDI 5724 3153 2571
GHQ 5811 3211 2600
MBI 3379 1745 1634
GSS 5633 3096 2537
BDI; Beck Depression Inventory.
GHQ; General Health Questionnaire.
MBI; Maslach Burnout Inventory.
GSS; Global Seasonality Score.
doi:10.1371/journal.pone.0071450.t001
CRY2 and Dysthymia
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Table 2. Successfully genotyped SNPs, their selection criteria, allele and genotype frequencies, and Hardy-Weinberg equilibrium
p-values.
Gene SNP BP A1 A2 MAF A1A1 A1A2 A2A2 HWE-P Selection criteria
TTC1 rs6878309 159358102 C T 0.09 57 (0.01) 990 (0.17) 4800 (0.82) 0.44 LD
TTC1 rs1402024 159361425 G A 0.02 1 (0) 177 (0.03) 5636 (0.97) 1 LD
TTC1 rs41275305 159370449 G C 0 0 (0) 31 (0.01) 5815 (0.99) 1 non-synonymous coding variant
TTC1 rs10515804 159380041 T C 0.3 531 (0.09) 2468 (0.43) 2797 (0.48) 0.71 LD
TTC1 rs2176830 159380714 A G 0.07 32 (0.01) 756 (0.13) 5057 (0.87) 0.48 LD
TTC1 rs12520927 159410735 G 0 0 (0) 0 (0) 5854 (1) 1 non-synonymous coding variant
TTC1 rs3733869 159422128 T C 0.3 522 (0.09) 2430 (0.42) 2866 (0.49) 0.83 LD
TTC1 rs6861719 159422825 T C 0.23 295 (0.05) 2066 (0.36) 3448 (0.59) 0.55 LD
TTC1 rs1106055 159424098 A G 0.32 607 (0.1) 2517 (0.43) 2674 (0.46) 0.7 LD
TTC1 rs7715826 159425636 T C 0.02 5 (0) 254 (0.04) 5595 (0.96) 0.22 LD
CRY2 rs7121611 45820718 A T 0.46 1218 (0.21) 2883 (0.5) 1711 (0.29) 0.96 LD
CRY2 rs7121775 45820899 C T 0.27 384 (0.07) 2326 (0.4) 3100 (0.53) 0.06 LD
CRY2 rs61884508 45821508 G T 0.02 1 (0) 241 (0.04) 5600 (0.96) 0.52 Pupasuite OregannoFilter TFBS
CRY2 rs75065406 45821518 T C 0.04 13 (0) 421 (0.07) 5414 (0.93) 0.11 TFBS, MAF
CRY2 rs3747548 45825589 A C 0 0 (0) 1 (0) 5847 (1) 1 Pupasuite non-synonymous & VarioWatch
CRY2 rs10838524 45826753 G A 0.48 1337 (0.23) 2897 (0.5) 1579 (0.27) 0.92 LD & Lavebratt et al.
CRY2 rs2292913 45834105 T C 0.05 18 (0) 590 (0.1) 5233 (0.9) 0.7 LD & splice site
CRY2 rs7945565 45835568 G A 0.46 1213 (0.21) 2890 (0.5) 1695 (0.29) 0.79 Pupasuite Triplex
CRY2 rs1401419 45836315 G A 0.46 1211 (0.21) 2909 (0.5) 1681 (0.29) 0.48 Pupasuite Triplex
CRY2 rs72902437 45838834 C T 0.03 2 (0) 313 (0.05) 5499 (0.95) 0.45 Pupasuite Triplex
CRY2 rs35488012 45845804 G 0 0 (0) 0 (0) 5854 (1) 1 Variowatch synonymous
CRY2 rs7123390 45847994 A G 0.29 431 (0.07) 2445 (0.42) 2915 (0.5) 0.01 LD & Lavebratt et al.
CRY2 rs4755345 45848084 A G 0.05 18 (0) 598 (0.1) 5229 (0.89) 0.8 LD
CRY2 rs17787136 45851212 G C 0.28 409 (0.07) 2385 (0.41) 3014 (0.52) 0.03 Pupasuite TFBS
CRY2 rs10838527 45859770 G A 0.12 89 (0.02) 1236 (0.21) 4509 (0.77) 0.67 LD & Lavebratt et al.
CRY2 rs2292910 45860189 A C 0.34 650 (0.11) 2707 (0.47) 2455 (0.42) 0.02 LD & dbSMR miRNA target site
CRY2 rs3824872 45862181 T G 0.25 372 (0.06) 2173 (0.37) 3276 (0.56) 0.65 LD & Lavebratt et al.
CRY2 rs1554338 45863406 G A 0.05 14 (0) 528 (0.09) 5289 (0.91) 0.77 LD
CRY1 rs4964513 105899888 C T 0.12 84 (0.01) 1224 (0.21) 4492 (0.77) 0.95 LD
CRY1 rs714359 105902975 A G 0.22 276 (0.05) 2006 (0.35) 3516 (0.61) 0.67 LD
CRY1 rs12821586 105904582 A G 0.11 72 (0.01) 1138 (0.19) 4629 (0.79) 0.84 LD
CRY1 rs2287161 105905270 C G 0.5 1408 (0.24) 2930 (0.51) 1461 (0.25) 0.43 Soria et al. & Utge et al. & Pupasuite triplex
CRY1 rs8192441 105909584 C A 0.01 1 (0) 136 (0.02) 5712 (0.98) 0.56 miRNASNP miRNA target site
CRY1 rs3741892 105911293 C G 0.49 1395 (0.24) 2937 (0.51) 1477 (0.25) 0.4 Pupasuite Triplex
CRY1 rs10861688 105918178 T C 0.17 164 (0.03) 1642 (0.28) 4011 (0.69) 0.82 LD
CRY1 rs10861697 105943792 C G 0.49 1352 (0.23) 2923 (0.5) 1521 (0.26) 0.48 Pupasuite Triplex
CRY1 rs2078074 105960936 C T 0.42 1017 (0.18) 2815 (0.49) 1930 (0.33) 0.87 Pupasuite Transfac
CRY1 rs59790130 105964433 T C 0.06 26 (0) 692 (0.12) 5131 (0.88) 0.58 Pupasuite Transfac
CRY1 rs10437895 105964954 C T 0.49 1398 (0.24) 2936 (0.5) 1482 (0.25) 0.46 Pupasuite Transfac
CRY1 rs10746077 105965682 A G 0.42 1027 (0.18) 2832 (0.49) 1960 (0.34) 0.96 Pupasuite Transfac
CRY1 rs11613557 105966445 T C 0.06 26 (0) 692 (0.12) 5130 (0.88) 0.58 Pupasuite Triplex
CRY1 rs2888896 105970712 T C 0.42 1019 (0.18) 2830 (0.49) 1947 (0.34) 0.87 LD
CRY1 rs11113179 105976915 T C 0.08 39 (0.01) 833 (0.14) 4942 (0.85) 0.53 LD & Utge et al.
CRY1 rs10746083 105978532 T C 0.49 1391 (0.24) 2941 (0.51) 1481 (0.25) 0.37 Pupasuite Triplex
CRY1 rs4964518 105990347 T C 0.07 30 (0.01) 778 (0.13) 5027 (0.86) 1 LD
CRY1 rs7294758 105991959 A T 0.01 0 (0) 97 (0.02) 5758 (0.98) 1 Pupasuite Triplex
CRY1 rs17289712 105993098 G A 0.05 6 (0) 524 (0.09) 5308 (0.91) 0.07 LD
CRY2 and Dysthymia
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were decided to be genotyped and all, except one (TTC1
rs3733868), were successfully included in the genotyping multi-
plexes. One SNP (CRY1 rs11113153) failed in the genotyping
phase.
In addition to the aforementioned SNPs, potentially functional
variants, as many as possible, were included in the genotyping
multiplexes. These 21 additional SNPs (8 for CRY2, 11 for CRY1
and 2 for TTC1) were selected using Pupasuite [35], Variowatch
[36], dbSMR [37] and miRNASNP [38] databases. Table 2
presents all the 48 SNPs that were successfully genotyped in this
study and their selection criteria.
Table 3. Results from the single SNP association analyses (q,0.15).
Phenotype Model Gene SNP A1 Odds ratio L95 U95 P-value Q-value
Dysthymia ADD CRY2 rs10838524 G 1.75 1.35 2.27 2.00E-05 0.04*
Dysthymia ADD women CRY2 rs10838524 G 1.97 1.44 2.71 2.60E-05 0.04*
Dysthymia DOM CRY2 rs10838524 G 3.27 1.84 5.83 5.90E-05 0.04*
Dysthymia DOM women CRY2 rs10838524 G 5.11 2.22 11.77 0.00013 0.07
Dysthymia ADD CRY2 rs1401419 G 1.71 1.32 2.21 4.10E-05 0.04*
Dysthymia ADD women CRY2 rs1401419 G 1.82 1.33 2.48 0.00018 0.07
Dysthymia DOM CRY2 rs1401419 G 2.67 1.59 4.46 0.0002 0.07
Dysthymia DOM women CRY2 rs1401419 G 3.20 1.65 6.23 0.00061 0.14
Depressive disorders DOM CRY2 rs1401419 G 1.62 1.23 2.13 0.00063 0.14
Dysthymia ADD CRY2 rs3824872 T 0.52 0.37 0.74 0.00024 0.08
Dysthymia ADD CRY2 rs7121611 A 1.74 1.35 2.24 2.20E-05 0.04*
Dysthymia ADD women CRY2 rs7121611 A 1.86 1.36 2.53 9.40E-05 0.06
Dysthymia DOM CRY2 rs7121611 A 2.74 1.63 4.58 0.00013 0.07
Depressive disorders DOM CRY2 rs7121611 A 1.66 1.26 2.18 0.00033 0.1
Dysthymia DOM women CRY2 rs7121611 A 3.30 1.7 6.42 0.00043 0.12
Dysthymia ADD CRY2 rs7945565 G 1.71 1.33 2.21 3.90E-05 0.04*
Dysthymia ADD women CRY2 rs7945565 G 1.82 1.33 2.49 0.00017 0.07
Dysthymia DOM CRY2 rs7945565 G 2.68 1.6 4.49 0.00018 0.07
Depressive disorders DOM CRY2 rs7945565 G 1.65 1.25 2.17 0.00042 0.12
Dysthymia DOM women CRY2 rs7945565 G 3.22 1.65 6.26 0.00058 0.14
ADD; Additive model.
DOM; Dominant model.
A1; Tested allele (minor allele).
L95, U95; Lower and upper bounds of 95% confidence interval for odds ratio.
*Significant association.
doi:10.1371/journal.pone.0071450.t003
Table 2. Cont.
Gene SNP BP A1 A2 MAF A1A1 A1A2 A2A2 HWE-P Selection criteria
CRY1 rs10778528 105998092 G T 0.48 1358 (0.23) 2926 (0.5) 1533 (0.26) 0.62 LD
BP; Base pair position based on NCBI36/hg18 build.
A1; Minor allele.
A2; Major allele.
MAF; Minor allele frequency.
A1A1, A1A2, A2A2; genotype counts and frequencies (%).
HWE-P; Hardy-Weinberg equilibrium p-value.
LD; Linkage disequilibrium.
TFBS, Transcription factor binding site.
doi:10.1371/journal.pone.0071450.t002
CRY2 and Dysthymia
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Genotyping
Genomic DNA was isolated from the whole blood according to
standard procedures. DNA samples were available from 5910
subjects for this study. The SNPs were genotyped using the
Sequenom MassARRAY system and the iPLEX Gold Single Base
Extension chemistry (Sequenom, San Diego, CA, USA) in a
multiplex format [39]. This method has excellent success (.95%)
and accuracy (100%) rates [40]. For the genotyping quality control
purposes, both positive (CEPH) and negative water controls were
included in each 384-plate. Genotyping was performed blind to
phenotypic information.
173 individuals were removed from the statistical analyses due
to a high missing genotype rate (i.e. .0.1). The total genotyping
rate in the remaining individuals was 0.9987. In addition, the
following five SNPs were removed because of the minor allele
frequency of ,0.01: rs41275305, rs12520927, rs3747548,
rs35488012, rs7294758. Finally, there were 5737 individuals and
43 SNPs for the statistical analyses.
Statistical Analyses
Statistical analyses were performed with the PLINK software
[41], release v1.07. The additive model was calculated using
logistic and linear regression models controlling for age and sex.
In addition, dominant and recessive models were calculated and
the analyses were performed in both sexes separately. For
continuous phenotypes 10,000 permutations were used to
produce empirical p-values in order to relax the assumption
of normality. The results were corrected for multiple testing
across all the tests (SNPs, phenotypes, gender, genetic models)
by calculating false discovery rate (FDR) q-values [42] using R
software (http://www.r-project.org/). The q-values of ,0.05
were considered significant.
Figure 1. The analyzed CRY1 SNPs in this study, their location and the haplotype block structure of the area formed based on our
sample showing r2 values. The confidence interval algorithm implemented in the Haploview program was used to construct the haplotype
blocks.
doi:10.1371/journal.pone.0071450.g001
CRY2 and Dysthymia
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Haploview software [34] was used to define haplotype blocks by
the confidence interval method. Each haplotype in the formed
blocks was analyzed by PLINK software using linear and logistic
regression, additive model and controlling for age and sex. Sexes
were also analyzed separately. Continuous phenotypes were
permuted 10,000 times. Interactions between CRY2 and TTC1
(SNP 6 SNP epistasis) were tested and calculated using the
PLINK software.
Results
The genotype and allele frequencies and Hardy-Weinberg
equilibrium (HWE) estimates are shown in Table 2 (see Table S1
for the genotype counts by phenotype). The results of the
association analyses where q,0.15 are presented in Table 3 and
the remaining results of the association analyses in Table S2. Four
CRY2 SNPs showed evidence of association with dysthymia using
the additive model (rs10838524 risk allele G, p = 0.000020,
OR=1.75; rs7121611 risk allele A, p = 0.000022, OR=1.74;
rs7945565 risk allele G, p = 0.000039, OR=1.71; rs1401419 risk
allele G, p = 0.000041, OR=1.71). CRY2 SNP rs10838524
showed evidence of association also using the dominant model
(p = 0.000059, OR=3.27) and the additive model for women
(p = 0.000026, OR=1.97). The CRY1 and TTC1 genetic variants
studied showed no evidence of association with any of the
phenotypes analyzed. No epistasis between CRY2 and TTC1 SNPs
was observed.
Haploview produced two haplotype blocks for CRY1 (Figure 1),
one for CRY2 (Figure 2) and one for TTC1 (Figure 3). The
haplotype analyses supported the association of CRY2 with
dysthymia, as the ATTCGCGGTGGCACG haplotype contain-
ing the risk alleles A, G, G and G of SNPs rs7121611, rs10838524,
rs7945565 and rs1401419, respectively, showed association with
dysthymia in all cases (p = 0.00034, OR=1.58) and among
women (p = 0.0011, OR=1.66). Table 4 presents the haplotype
associations with p-values (or empirical p-values) of ,0.010.
Discussion
Our main finding was that CRY2 genetic variants associated
with dysthymia in our random sample derived from the general
population aged 30 years and older. The associations with
dysthymia were stronger in the additive than in the dominant
model and became weaker when we analyzed only women
(n= 88). No association was observed in men. The sample size for
dysthymia was limited (n = 128) and the lack of association in men
could be due to a small sample size (n = 40). We did not find any
significant association of CRY2 with major depressive disorder,
whether with a single or recurrent episode, or with anxiety
disorders, and there was no significant association of CRY1 or
TTC1 with any of the phenotypes assessed.
Of the individual CRY2 SNPs, rs7121611 (upstream),
rs10838524 (intron 1), rs7945565 (intron 2) and rs1401419 (intron
2) showed evidence of association with dysthymia, with the A, G, G
and G alleles being predisposing, respectively. These associations
are supported by the haplotype analysis, as the CRY2
ATTCGCGGTGGCACG haplotype including the individual risk
alleles associated with the phenotype. The associated haplotype of
CRY2 spans almost the whole gene and the four associated SNPs
are located in the first half of the haplotype block (Figure 2).
Figure 2. The analyzed CRY2 SNPs, their location and the haplotype block structure constructed using the Haploview program
showing r2 values.
doi:10.1371/journal.pone.0071450.g002
CRY2 and Dysthymia
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According to transcription factor CHiPSeq from ENCODE
(http://genome.ucsc.edu/ENCODE/) SNP rs10838524 is located
in a regulatory region and according to Pupasuite software [35]
rs7945565 and rs1401419 were predicted to be putative triplex
disrupting SNPs which may also be part of regulatory regions for
controlling gene expression [43].
Of the four associated CRY2 SNPs, only rs10838524 has
previously been linked to mental health disorders. Concerning this
SNP, our current results are partly in line with the findings of
Lavebratt et al. [24] who found the same risk allele for winter
depression in the Finnish subpopulation of their study. The allele
frequencies in cases and controls were similar in these two sets, as
expected for the controls, since they were drawn from the same
Health 2000 cohort. The cases, on the other hand, had been
recruited from outpatient services in the capital area [24]. Another
Finnish study, using a population based sample also from the
Health 2000 cohort, found the same minor allele to weakly
associate with depressive disorders in women and in women
having depressive disorders with early morning awakening, and
the association was supported with haplotype analyses but did not
hold after correcting for multiple testing [44]. We also analyzed
depressive disorders in women and found similar crude p-value
(p = 0.035, Table S2). In the study by Utge et al., the statistical
analyses had been done separately in men and women. In our
analyses, the associations were stronger when using the dominant
model in both sexes together (p = 0.0010), but still the association
to depressive disorders did not reach statistical significance after
correcting for multiple testing. For the Swedish subpopulation of
the winter depression study [24] as well as for a Swedish bipolar
study [25], the allele frequencies for CRY2 rs10838524 were
reversed and the other allele, i.e. A, was found as the risk allele.
Earlier, the A allele has also been associated with a greater degree
of chronic course of depressive symptoms in a sample of 35
individuals with major depression or bipolar disorder [45].
Concerning SNP rs3824872, located in the 39 region of CRY2
(but also in the 59 region of MAPK8IP1 gene), our study suggests
(q = 0.08) that the T allele is the protective one against dysthymia,
and a similar (though non-significant) tendency is seen in the
Finnish subpopulation of the winter depression study [24], while in
the Swedish subpopulation of the same study, the other allele, i.e.
A, was the risk allele. With regard to CRY2 rs7123390, the SNP
was earlier associated with winter depression in the Finnish
subpopulation [24], but in the current study, we did not observe
any significant association with this intronic SNP. Moreover, there
was no significant association with the 39UTR CRY2 rs10838527,
similar to earlier findings where no association with winter
Figure 3. The analyzed TTC1 SNPs, their location and the haplotype block structure constructed using the Haploview program
showing r2 values.
doi:10.1371/journal.pone.0071450.g003
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depression was observed among the Finnish subpopulation,
whereas this SNP did associate with winter depression among
the Swedish subpopulation [24].
Although preliminary, our analysis has demonstrated that CRY2
associates robustly with dysthymia which is characterized by a
chronic course of illness where a depressive episode lasts for two
years or longer and often deepens into a major depressive episode.
Earlier, CRY2 genetic variants have been associated with winter
recurrent depressive disorder [24], and with the rapid cycling of
bipolar type 1 disorder where depressive episodes dominate the
clinical course of illness [25]. A single CRY1 variant has been
associated with major depressive disorder earlier [23] but there is
no replication of the finding [21]. Furthermore, it has been
previously observed that following the antidepressant sleep
deprivation, the expression of CRY2 mRNA increased in controls,
whereas no change or response to the treatment was observed in
patients with bipolar disorder whose CRY2 mRNA levels were
markedly lower than in controls [24]. Moreover in an animal
study, CRY2 mRNA expression was abnormal when inbred-strain
mice with the intrinsic level of high anxiety were deprived of sleep
[46]. Currently, it is however not known, whether the knock-out or
the knock-down of CRY2 in the whole organism or specific to a
tissue produces any change in anxiety-like or depressive-like
behaviors, or how mutated CRY2 proteins influence mood-related
behaviors. CRY2 and CRY1 proteins are functionally different [7]
which could impact their circadian outputs differently and make a
difference in the consequent phenotype. This difference could
explain why CRY2, not CRY1, associated with dysthymia in our
study. Moreover, it might be that CRY2 variants play a leading role
in circadian hierarchy [3] and thereby in the pathogenesis of mood
disorders as well. Some circadian clock gene variants seem to have
a role in neuropsychiatric disorders in general [47,48]. Elucidating
the mechanisms of action with these genetic variants might
therefore benefit the development of treatments for and beyond
mood and anxiety disorders [18,49,50].
A limitation in our current epidemiological health examination
study is that the seasonal pattern, whether in major depressive
disorder or bipolar disorder, was not assessed at all. Another
limitation is that the diagnoses of bipolar disorders were
considered not adequate for analysis. However, it is of note that
bipolar type 1 disorder is markedly less frequent in Finland
compared with the prevalence in many Western-type societies
[51].
To conclude, CRY2 genetic variants associated with dysthymia.
This new data, together with the earlier findings, reinforces the
involvement of CRY2 in mood disorders.
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